~~<i id='1CD4809415'><strike id='1CD4809415'><tt id='1CD4809415'><pre id='1CD4809415'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：fashion 2025-09-29 05:00:32 Page View：5

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： California store owner shot dead in dispute over displaying Pride flag: Police
Next article： Medical records are filled with copy

explore

Guidelines to prevent youth baseball injuries need more muscle

Apitcheratthe2018LittleLeagueWorldSeries.RobCarr/GettyImages“Weallknowthatweareinthemiddleofanepidem

Roche's accidental data boosts hopes for anti

SEBASTIENBOZON/AFPviaGettyImagesThemultibillion-dollarhuntforwhatmanydrugmakershopewillbethenextbigi

Moonlake's readout produced a cash windfall. Risks remain

MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

What could happen if Russia blows up the Zaporizhzhia Nuclear Power Plant?

2:30ResidentspassalongastreetinNikopol,withtheZaporizhzhiaNuclearPowerPlantinthebackground,behindane